U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07191912) titled 'Confirmatory Study of Govorestat in CMT-SORD' on Sept. 10.
Brief Summary: This study is designed to assess the long-term efficacy and clinical benefit of AT-007 in patients with CMT-SORD. This randomized, double-blind study will assess the effect of govorestat compared to placebo in patients with CMT-SORD for up to 36 months.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Charcot-Marie-Tooth Disease With Sorbitol Dehydrogenase Deficiency (CMT-SORD)
Intervention:
DRUG: Govorestat
Govorestat will be provided as a liquid suspension (200mg/mL) for weight-based administration and administered orally at 20 mg/k...